Company: DNLI
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001714899-25-000193
Chunk: 184

Company: Denali Therapeutics Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 184
---
 — Stock-based compensation— — 78,188 — — 78,188 Net loss— — — — (308,020)(308,020)Other comprehensive income— — — 4,886 — 4,886 Balance at September 30, 2024143,840,029 $1,764 $2,735,433 $5,529 $(1,424,231)$1,318,495 Balance at June 30, 2024143,123,582 $1,757 $2,704,992 $(2,659)$(1,317,039)$1,387,051 Issuances under equity incentive plans291,183 3 5,453 — — 5,456 Vesting of restricted stock units425,264 4 (4)— — — Stock-based compensation— — 24,992 — — 24,992 Net loss— — — — (107,192)(107,192)Other comprehensive income— — — 8,188 — 8,188 Balance at September 30, 2024143,840,029 $1,764 $2,735,433 $5,529 $(1,424,231)$1,318,495 

See accompanying notes to unaudited condensed consolidated financial statements.

5

Denali Therapeutics Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

Nine Months EndedSeptember 30,20252024Operating activitiesNet loss$(383,991)$(308,020)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization8,317 5,942 Stock–based compensation expense75,682 77,800 Net accretion of discounts on marketable securities(8,611)(28,952)Non-cash adjustment to operating lease expense(3,305)(3,025)Right-of-use asset amortization for finance lease2,713 431 Non-cash gain from divestiture of small molecule programs— (14,537)Changes in operating assets and liabilities:Prepaid expenses and other current assets(2,287)(2,625)Other non-current assets1,305 (1,178)Accounts payable(4,112